health

Biogen and Denali Therapeutics announced on May 21, 2026 that their experimental Parkinson's drug BIIB122 (also called DNL151) failed a Phase 2b clinical trial called LUMA. The drug is a LRRK2 inhibitor — meaning it was designed to block an enzyme called LRRK2 (leucine-rich repeat kinase 2) that, when overactive, is thought to damage brain cells in Parkinson's disease. The LUMA trial tested whether the drug could slow disease progression in people with early-stage, "idiopathic" Parkinson's (meaning not caused by a known genetic mutation). It did not: patients on the drug did not fare better than those on placebo on any of the trial's main or secondary measures. On the positive side, the drug was well-tolerated, and lab tests confirmed it was reaching the brain and blocking LRRK2 activity — so the problem appears to be that blocking LRRK2 simply does not slow disease progression in the general Parkinson's population, not that the drug failed to work as designed.

There is a meaningful silver lining. A separate, smaller trial called BEACON continues — this one enrolls only people who carry a mutation in the LRRK2 gene itself, where the enzyme is thought to play a more direct disease-causing role. Results from BEACON are expected in the first half of 2027. If you or a family member carry an LRRK2 mutation (most commonly LRRK2-G2019S, found more often in people of Ashkenazi Jewish or North African Berber descent), this trial is still active and the question of whether LRRK2 inhibition helps that group remains open.

For most people living with Parkinson's, this is a setback — one of the more advanced disease-modifying drug programmes in the pipeline has now been discontinued for the general population. It does not affect current symptom-management treatments in any way. It is a reminder that translating a promising biological target into an effective therapy is hard, and that the field still lacks a proven way to slow or stop the disease. Research continues on many other fronts.